drugset / Trial / NCT05155657

Study of Decompensated Alcoholic Cirrhosis Treatment by Stem Cells

NCT05155657

Phase 1 Unknown 36 enrolled Yantai Yuhuangding Hospital
Non-randomizedSequentialSingle-blindTreatment

Summary

The main purpose of this study is to evaluate the safety and tolerance of umbilical cord mesenchymal stem cells (UCMSCs) in patients with decompensated alcoholic cirrhosis, and to provide dose basis for subsequent clinical study design. We will also explore the possible mechanism of UCMSCs in the treatment of decompensated alcoholic cirrhosis (DAC).

Timeline

Start
2022-06-13
Primary completion
2024-12-25
Completion
2024-12-25

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 500000 cells/kg Intravenous
Subject mesenchymal stem cells Cell therapy 1e+06 cells/kg Intravenous
Subject mesenchymal stem cells Cell therapy 2e+06 cells/kg Intravenous